Krystal Biotech (NASDAQ:KRYS), a gene therapy company for rare dermatological diseases announced financial results for 2017 and an update on its business progress. As quoted in the press release: “2018 promises to be a productive and exciting year for Krystal. Our successful IPO last year has positioned us to build a fully integrated company dedicated …

Krystal Biotech (NASDAQ:KRYS), a gene therapy company for rare dermatological diseases announced financial results for 2017 and an update on its business progress.

As quoted in the press release:

“2018 promises to be a productive and exciting year for Krystal. Our successful IPO last year has positioned us to build a fully integrated company dedicated to discovering, developing and delivering off-the-shelf easy to administer chronic treatments for rare dermatological diseases that provide transformative outcomes to patients and families,” said Krish S. Krishnan, Chief Executive Officer of Krystal Biotech. “Our immediate focus is to execute on our planned Phase 1/2 clinical study for our lead product candidate KB103 for treatment of Dystrophic Epidermolysis Bullosa, and to file an IND in the fourth quarter for our second product candidate, KB105 for the treatment of Lamellar Ichthyosis. In parallel, we are building out our infrastructure with the goal of establishing a GMP facility in Pittsburgh, PA in the next 12 months for the production of our pipeline products using our STAR-D (Skin Targeted Delivery) platform.”

Click here to read the full press release.